(5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-naphthalen-2-ylamine | 92872-51-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: (5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-naphthalen-2-ylamine
• 英文别名: (5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)naphthalen-2-ylamine；5-methyl-N-(2-naphthyl)[1,2,4] triazolo [1,5-a]pyrimidin-7-amine；DSM1；MB1_A_011099A-3；MMV011099；(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-naphthalen-2-yl-amine；5-Methyl-n-(naphthalen-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine；5-methyl-N-naphthalen-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
• CAS: 92872-51-0
• 化学式: C₁₆H₁₃N₅
• 分子量: 275.313
• InChiKey: WPVMVODGPNYYEV-UHFFFAOYSA-N

物化性质

• 熔点：
  220 °C
• 密度：
  1.34±0.1 g/cm3(Predicted)
• 溶解度：
  DMSO: 50mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  7-氯-5-甲基-1,2,4-三唑并[1,5-Alpha]嘧啶 、 2-萘胺 以 乙醇 为溶剂， 反应 14.0h， 以86%的产率得到(5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-naphthalen-2-ylamine
  参考文献：
  名称：

  WO2007/149211

  摘要：

  公开号：

文献信息

• Triazolopyrimidine-Based Dihydroorotate Dehydrogenase Inhibitors with Potent and Selective Activity against the Malaria Parasite <i>Plasmodium falciparum</i>
  作者：Margaret A. Phillips、Ramesh Gujjar、Nicholas A. Malmquist、John White、Farah El Mazouni、Jeffrey Baldwin、Pradipsinh K. Rathod

  DOI：10.1021/jm8001026

  日期：2008.6.1

  A Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitor that is potent (K(I) = 15 nM) and species-selective (>5000-fold over the human enzyme) was identified by high-throughput screening. The substituted triazolopyrimidine and its structural analogues were produced by an inexpensive three-step synthesis, and the series showed good association between PfDHODH inhibition and parasite toxicity. This study has identified the first nanomolar PfDHODH inhibitor with potent antimalarial activity in whole cells (EC(50) = 79 nM).
• DIHYDROOROTATE DEHYDROGENASE INHIBITORS WITH SELECTIVE ANTI-MALARIAL ACTIVITY
  申请人：Phillips Margaret

  公开号：US20080027079A1

  公开（公告）日：2008-01-31

  Pharmaceutical compositions comprising compounds of the formula where R 1 , R 2 , and R 3 are described here, have therapeutic utility in selectively inhibiting P. falciparum dihydroorotate dehydrogenase. Accordingly, such compositions have use in the treatment and prevention of malaria.
• NOVEL METHODS FOR TREATING NEURODEGENERATIVE DISEASES
  申请人：GENZYME CORPORATION

  公开号：US20160287549A1

  公开（公告）日：2016-10-06

  The invention relates to dihydroorate dehydrogenase (DHODH) inhibitors useful for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis.
• MALONATE SALT OF VARLITINIB
  申请人：Aslan Pharmaceuticals PTE LTD

  公开号：US20210379070A1

  公开（公告）日：2021-12-09

  The present disclosure relates to a pharmaceutically acceptable salt of compounds (I), i.e. varlitinib, a method of producing the salt, a purer form of the free base obtainable from the salt, and a pharmaceutical composition comprising any one of the same. Also provided is a salt, free base or composition thereof for use in treatment, in particular the treatment of cancer, including as part of a combination therapy, for example in combination with a chemotherapeutic agent. The disclosure also extends to compositions comprising the same and use of any one of the same in treatment, in particular treatment of cancer.
• [EN] DIHYDROOROTATE DEHYDROGENASE INHIBITORS WITH SELECTIVE ANTI-MALARIAL ACTIVITY<br/>[FR] INHIBITEURS DE LA DIHYDROOROTATE DÉSHYDROGÉNASE AVEC ACTIVITÉ ANTI-MALARIQUE SÉLECTIVE
  申请人：UNIV TEXAS

  公开号：WO2007149211A1

  公开（公告）日：2007-12-27

  [EN] Pharmaceutical compositions comprising compounds of the formula (I) where R¹, R², and R³ are described here, have therapeutic utility in selectively inhibiting P. falciparum dihydroorotate dehydrogenase. Accordingly, such compositions have use in the treatment and prevention of malaria.
  [FR] L'invention concerne des compositions pharmaceutiques comprenant des composés de la formule (I), dans laquelle R¹, R², et R³ sont décrits ici, ayant une utilité thérapeutique pour inhiber sélectivement la dihydroorotate déshydrogénase de P. falciparum. En conséquence, de telles compositions ont une utilisation dans le traitement et la prévention de la malaria.